%0 Journal Article
%A Schaffrath, Anja
%A Schleyken, Sophia
%A Seger, Aline
%A Jergas, Hannah
%A Özdüzenciler, Pelin
%A Pils, Marlene
%A Blömeke, Lara
%A Cousin, Anneliese
%A Willbold, Johannes
%A Bujnicki, Tuyen
%A Bannach, Oliver
%A Fink, Gereon R.
%A Willbold, Dieter
%A Sommerauer, Michael
%A Barbe, Michael T.
%A Tamgüney, Gültekin
%T Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool
%J npj Parkinson's Disease
%V 9
%N 1
%@ 2373-8057
%C London [u.a.]
%I Nature Publ. Group
%M FZJ-2023-01236
%P 14
%D 2023
%X Misfolded and aggregated α-synuclein is a neuropathological hallmark of Parkinson’s disease (PD). Thus, α-synuclein aggregates are regarded as a biomarker for the development of diagnostic assays. Quantification of α-synuclein aggregates in body fluids is challenging, and requires highly sensitive and specific assays. Recent studies suggest that α-synuclein aggregates may be shed into stool. We used surface-based fluorescence intensity distribution analysis (sFIDA) to detect and quantify single particles of α-synuclein aggregates in stool of 94 PD patients, 72 isolated rapid eye movement sleep behavior disorder (iRBD) patients, and 51 healthy controls. We measured significantly elevated concentrations of α-synuclein aggregates in stool of iRBD patients versus those of controls (p = 0.024) or PD patients (p < 0.001). Our results show that α-synuclein aggregates are excreted in stool and can be measured using the sFIDA assay, which could support the diagnosis of prodromal synucleinopathies.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ 36732520
%U <Go to ISI:>//WOS:001002245600001
%R 10.1038/s41531-023-00458-4
%U https://juser.fz-juelich.de/record/1002038